BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, June 3, 2026
Home » Authors » Sergio Held

Sergio Held

Articles

ARTICLES

Costs on the rise as Brazil's Anvisa introduces new rules

Oct. 30, 2014
By Sergio Held
BOGOTA, Colombia – In a move that could lead to sharp increases in the operational timing and costs of introducing generic and subsequent entry of biologic drugs into the Brazilian market, Brazil's National Health Surveillance Agency (Anvisa) updated its guidelines for the issuance of certificates of good practice of bioavailability and bioequivalence studies for both domestic and international labs.
Read More

Latin America: Colombians develop component to stop bleeding from liver punctures

Oct. 20, 2014
By Sergio Held

Cuba to strengthen cooperation with China in biopharma production

Oct. 20, 2014
By Sergio Held
BOGOTA, Colombia – Cuban and Chinese authorities are working together to boost the island´s biotech production through a series of bilateral cooperation agreements that have been in place since 2001.
Read More

Brazil's Anvisa suspends Meningitec vaccine

Oct. 17, 2014
By Sergio Held
The surveillance agency of Brazil's Ministry of Health (Anvisa) suspended on Thursday the distribution and commercialization of the meningococcal serogroup C conjugate vaccine Meningitec, following a global recall by its owner Nuron Biotech Inc., of Exton, Pa.
Read More

Cuba to strengthen cooperation with China in biopharma production

Oct. 15, 2014
By Sergio Held
BOGOTA, Colombia – Cuban and Chinese authorities are working together to boost the island´s biotech production through a series of bilateral cooperation agreements that have been in place since 2001.
Read More

Report from Costa Rica: Theragenics to open new med-tech plant in Costa Rica

Oct. 10, 2014
By Sergio Held

Report from Latin America: Costa Rica to premiere masters in medical device engineering

Oct. 9, 2014
By Sergio Held

With office in Mexico, Mundipharma boosts Latin America presence

Oct. 9, 2014
By Sergio Held
BOGOTA, Colombia – With the recent announcement of the opening of a new office in Mexico City, Mundipharma International Corp. Ltd. is strengthening its presence in Latin America, a region that the Singapore company considers strategic for its business.
Read More

Latin America: Dominican Republic boosts position as a strategic med-tech manufacturer

Sep. 30, 2014
By Sergio Held

Colombia issues new biotech regulations

Sep. 23, 2014
By Sergio Held
BOGOTA, Colombia – After years of heated debate, Colombian President Juan Manuel Santos and the Ministry of Health signed a decree establishing biotechnology regulations for the country's pharma industry.
Read More
View All Articles by Sergio Held

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 2, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 2, 2026
  • Pancreas 3D hologram

    ASCO 2026: A revolution in pancreatic cancer

    BioWorld
    At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
  • Healthy (left) vs. cancerous bone marrow

    BMS’ mezigdomide doubles PFS in multiple myeloma

    BioWorld
    Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
  • Antibodies attacking cancer cell

    ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal

    BioWorld
    Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing